Compare Iris Energy Limited (IREN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

IREN trades at $40.20, up 19.57% in 24 hours but remains volatile amid a broader AI infrastructure stock sell-off. The stock shows a bearish technical signal with support at $31 and resistance at $36. Fundamentally, revenue grew to $501M in 2025 with a 20.88% net income margin, but recent quarters missed EPS expectations. The company is transitioning from Bitcoin mining to AI cloud services, with significant capital investment driving negative cash flow from investing activities.

Wall Street maintains a bullish stance with a $79.11 consensus price target and 71% buy ratings, citing IREN's AI infrastructure potential. However, execution risks, competitive pressures from Meta and peers, and recent earnings misses pose significant challenges. The stock's high valuation multiples (P/E 43.66) require flawless growth execution to justify current levels.

RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.

The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.